RO 7082859

Drug Profile

RO 7082859

Alternative Names: RO-7082859

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors; CD3 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 13 Mar 2018 Phase-I clinical trials in Diffuse large B cell lymphoma (Combination therapy, Treatment-naive) in Denmark and Spain (IV) (NCT03467373)
  • 13 Mar 2018 Phase-I clinical trials in Follicular lymphoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in Denmark and Spain (IV) (NCT03467373)
  • 07 Feb 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (Metastatic disease) in Australia, Denmark, France, Italy and Spain (IV) (NCT03075696)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top